ストックスクリーナーアプリを入手
8.31
1.24%
0.26
Altimmune Inc (ALT) 最新ニュース
FY2024 EPS Estimates for Altimmune Reduced by HC Wainwright - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Receives $20.00 Consensus Target Price from Analysts - MarketBeat
(ALT) Trading Report - Stock Traders Daily
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 - Marketscreener.com
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 - The Manila Times
Altimmune's Pemvidutide Shows 68.5% Liver Fat Reduction in Phase 1b Trial Results | ALT Stock News - StockTitan
What is B. Riley's Forecast for Altimmune FY2024 Earnings? - MarketBeat
AMERIPRISE FINANCIAL INC's Strategic Acquisition in Altimmune Inc - GuruFocus.com
B. Riley Weighs in on Altimmune's Q1 Earnings (NASDAQ:ALT) - MarketBeat
Altimmune (NASDAQ:ALT) Given Buy Rating at HC Wainwright - MarketBeat
Altimmune Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge (NASDAQ:ALT) - Seeking Alpha
Altimmune Unusual Options Activity For November 13 - Benzinga
Altimmune’s Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver Health (ALT) - Seeking Alpha
Altimmune provided key pipeline updates with Q3 report, says B. Riley - TipRanks
Altimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call Transcript - Insider Monkey
UBS Initiates Coverage of Altimmune (ALT) with Buy Recommendation - Nasdaq
GSA Capital Partners LLP Sells 148,530 Shares of Altimmune, Inc. (NASDAQ:ALT) - MarketBeat
Earnings call: Altimmune reports progress on pemvidutide trials, financials - Investing.com India
Earnings call: Altimmune reports progress on pemvidutide trials, financials By Investing.com - Investing.com Canada
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding R&D Investments - GuruFocus.com
Altimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ... - Yahoo Finance
Altimmune (ALT) Stock Soars 27%: Phase 2 Data On Obesity Drug Ignites Market Optimism - Barchart
Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline - TipRanks
Altimmune Stock Rallies 30% on Updates - citybiz
Altimmune stock rallies 30% on business updates, UBS buy rating - MSN
Altimmune stock rallies 30% on business updates, UBS buy rating (NASDAQ:ALT) - Seeking Alpha
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traders Purchase Large Volume of Altimmune Call Options (NASDAQ:ALT) - MarketBeat
Altimmune Inc Reports Q3 2024 Results: GAAP EPS of -$0.32 Beats Estimates, Revenue at $5,000 - GuruFocus.com
Altimmune Appoints Gregory Weaver as CFO for Growth - TipRanks
UBS Group Initiates Coverage on Altimmune (NASDAQ:ALT) - MarketBeat
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance
Altimmune Stock Goes Parabolic Following Q3 Results As CEO Touts 2025 As ‘Transformational Year:’ Retail Upbeat - MSN
Altimmune Appoints Greg Weaver as CFO - citybiz
Altimmune Appoints Chief Financial Officer - Contract Pharma
Altimmune says ‘something raised attention of FDA’ - TipRanks
Altimmune appoints Greg Weaver as CFO - TipRanks
Altimmune Names Greg Weaver Chief Financial Officer - MarketWatch
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer - The Manila Times
TSX Communication Services Capped Index (TTTS) QuotePress Release - The Globe and Mail
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer - Marketscreener.com
How Altimmune Could Grab a Big Chunk of the GLP-1 Market - MarketBeat
Eli Lilly and Company (LLY-N) QuotePress Release - The Globe and Mail
Institutional investors control 59% of Altimmune, Inc. (NASDAQ:ALT) and were rewarded last week after stock increased 11% - Simply Wall St
Altimmune advances obesity treatment into Phase 3 trials By Investing.com - Investing.com South Africa
Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide - Seeking Alpha
Altimmune advances obesity treatment into Phase 3 trials - Investing.com India
Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity - The Manila Times
Altimmune Advances Obesity Drug: FDA Greenlights Major Phase 3 Program Design | ALT Stock News - StockTitan
Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times
Altimmune (ALT) to Present at Guggenheim and UBS Healthcare Conferences in November | ALT Stock News - StockTitan
How To Trade (ALT) - Stock Traders Daily
Altimmune (ALT) to Release Quarterly Earnings on Tuesday - MarketBeat
Altimmune’s stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss - MSN
Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 - StockTitan
Thinking about buying stock in Minim, Aurora Innovation, Altimmu - GuruFocus.com
Altimmune Awaits Results Of Fatty Liver Disease Drug Pemvidutide - RTTNews
Altimmune (NASDAQ:ALT) Trading Up 7%Here's What Happened - MarketBeat
Altimmune (ALT) Price Target Increased by 9.39% to 19.53 - MSN
Regulatory And Clinical Catalysts Ahead For Altimmune (NASDAQ:ALT) - Seeking Alpha
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):